Acquisition by Murray Stewart of 6854 shares of X4 Pharmaceuticals subject to Rule 16b-3
| XFOR Stock | USD 0.39 0.04 11.43% |
Slightly above 55% of X4 Pharmaceuticals' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding X4 Pharmaceuticals suggests that some traders are interested. X4 Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in X4 Pharmaceuticals. Many technical investors use X4 Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
XFOR |
Filed transaction by X4 Pharmaceuticals Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
X4 Pharmaceuticals Fundamental Analysis
We analyze X4 Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of X4 Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of X4 Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
X4 Pharmaceuticals is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
X4 Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with X4 Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of X4 Pharmaceuticals could also be used in its relative valuation, which is a method of valuing X4 Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
X4 Pharmaceuticals Related Equities
| HEPA | Hepion Pharmaceuticals | 4.69 | ||||
| ELEV | Elevation Oncology | 3.23 | ||||
| PDSB | PDS Biotechnology | 1.86 | ||||
| HOOK | Hookipa Pharma | 1.61 | ||||
| DAWN | Day One | 1.53 | ||||
| MREO | Mereo BioPharma | 1.40 | ||||
| ABOS | Acumen Pharmaceuticals | 0.44 | ||||
| INZY | Inozyme Pharma | 0.37 | ||||
| TERN | Terns Pharmaceuticals | 1.58 |
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.